Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALLOP: Semaglutide in Acute LVO Stroke
NCT05920889Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Aug 2023
- Primary completion
- Oct 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in ischemic stroke comparing Semaglutide Group with Standard of care (2 arms). Primary endpoints: Change of Modified Rankin Score at Day 90 and Composite Safety Outcome at Day 90. Started Aug 2023; status: completed.
02
Drugs
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05920889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05920889.